Navigation Links
Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Date:4/25/2008

- 85% of patients achieve undetectable HCV RNA levels following 4 weeks of

treatment with R7128 1500mg BID with Pegasys(R) plus Copegus(R) - - Safety and tolerability comparable to placebo administered with Pegasys

plus Copegus -

- EASL presentation available on Pharmasset website - - Conference call scheduled for Friday, April 25, 2008 at 1:00 PM ET (US)

and 7:00 PM CEST (Milan) -

PRINCETON, N.J. and MILAN, Italy, April 25 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces the results of a 4-week Phase 1 clinical trial evaluating two oral dose levels of R7128 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in 50 treatment-naive patients chronically infected with hepatitis C virus (HCV) genotype 1. R7128, a prodrug of PSI-6130, is a nucleoside analogue polymerase inhibitor of HCV that is being developed through Pharmasset's collaboration with Roche. The results of this study were presented today at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) being held from April 23-27, 2008 in Milan, Italy.

In this study, R7128 demonstrated potent short-term antiviral activity and was generally safe and well tolerated. Eighty-five percent (85%) of patients receiving R7128 1500mg twice-daily (BID) with Pegasys plus Copegus for 4 weeks achieved undetectable HCV RNA levels with safety and tolerability comparable to placebo with Pegasys plus Copegus.

Dr. John McHutchison, professor of medicine at Duke University Medical Center and a clinical investigator for this study, stated, "R7128, in combination with Pegasys plus Copegus, has demonstrated Rapid Virologic Response (RVR)
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
2. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
3. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
6. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
7. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
8. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
9. ACORN Presents Findings of Collaborative Metastatic Colorectal Cancer Research
10. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
11. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...c. 1 Vical Incorporated ... $1.0 million milestone payment from Merck & C...Phase I clinical trial of an investigational plasm...e is based on Vical,s DNA gene delivery technology...e (hTERT). hTERT is the subject of separate licens...
(Date:11/30/2008)... 1 Abnormalities in aud...children with autism spectrum disorder by using ma...resented today at the annual meeting of the Radiol... "Using MEG, we can record the tiny magnetic field... Timothy Roberts, Ph.D., vice chair of research in...
(Date:11/28/2008)... Nov. 28 Eli Lilly and C...tal New Drug Application (sNDA) from,the U.S. Foo...uloxetine HCl),for the management of chronic pain...first half of 2009, adding data from a recently co...pain of the knee. , The decision does not a...
(Date:11/26/2008)...nn., Nov. 26 Children w...significantly increased risk of developing mental ...of a Mayo Clinic study published this month in Pe...ademy of Pediatrics. , , The retrospective ... with strabismus (misaligned eyes) and compared th...
Breaking Medicine Technology:Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Eye Divergence in Children Triples Risk of Mental Illness 2FDA Clears Expanded Use of Xofts Axxent 28R 29 Electronic Brachytherapy System for all Radiation Therapy Indications 4003 1FDA Clears Expanded Use of Xofts Axxent 28R 29 Electronic Brachytherapy System for all Radiation Therapy Indications 4003 2New Study 3A Pycnogenol 28R 29 Improves Memory in Elderly 14480 1New Study 3A Pycnogenol 28R 29 Improves Memory in Elderly 14480 2New Study 3A Pycnogenol 28R 29 Improves Memory in Elderly 14480 3Millennium Expands IBD Franchise with Addition of New Development Candidate 14476 1Millennium Expands IBD Franchise with Addition of New Development Candidate 14476 2Millennium Expands IBD Franchise with Addition of New Development Candidate 14476 3Dragon retains leading investor relations firm 3999 1Dragon retains leading investor relations firm 3999 2Dragon retains leading investor relations firm 3999 3
...007 - Valeant,Pharmaceuticals International (NYSE:...ta for retigabine, a first-in-class,neuronal potas...endent, scientific journal. The authors concluded ...d reduction in monthly,seizure rates in this study...2) are currently underway to further investigate t...
...in-Free, WASHINGTON, April 10, 2007 /PRNewswire-US...cell therapy, the Journal of the,American Medical ...,14 of 15 Juvenile Diabetes patients demonstrated ...em cell treatment. According,to U.S. Rep. Dave Wel... it,s the first attempt at using stem cells of any...
Other Medicine Technology:Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology 2Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology 3Newest Adult Stem Therapy Treats Diabetes 2
(Date:12/1/2008)... at Memorial Sloan-Kettering Cancer Center, New Yo...expression of genes for therapeutic purposes, and ...in mice. , Small, noncoding RNA molecules known ...expression. In the study, the miRNA miR-181a was h...e cells known as T cells at different stages of th...
(Date:12/1/2008)...rstCall/ -- ViroPharma Incorporated,(Nasdaq: VP...supplemental,Biologics License Application (sBLA)...or Cinryze(TM) C1 Inhibitor (human) as a treatment.... , The sBLA is based on a re-analysis and ... treatment study of Cinryze and interim data from ...
(Date:12/1/2008)...y illnesses common, study shows , , MON...ers are common among young adults in the United St..., To reach this finding, U.S. researchers analy... to 25, who took part in the National Epidemiologi...he study found that 45.8 percent of the 2,188 coll...
(Date:12/1/2008)...Cancer Institute,s cancer registry has found that ...yed or incomplete radiation treatment following br...care can lead to worse outcomes. , Dr. Heather T...lleagues found that among a nationally representat...patients aged 65 and older, almost 1,300 women exp...
Breaking Medicine News(10 mins):Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 2Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 4Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 5Health News:Few Young Adults Seek Treatment for Psych Disorders 2Health News:Delays in radiation therapy lead to increased breast cancer recurrence 2
...new research, oxygen therapy at home reduces hospi... at the University Hospital of Denmark, have studi...er's lungs// - where the blood becomes deficient i... an outpatient clinic, then continued at home. Ha...
...e been studying about the outcome of the hitech sc... glucose uptake in a tumour shows who has a poor p...cts mainly younger people. //It's an unusual cance... unpredictable. Researchers at the University of G...
...s have found out that people under age 48 who suff...their healthy peers to have a defect in a gene cal...) combat the damaging effects of LDL (the bad chol... people, stroke is not a rare event in younger ind...
...cent study, a simple imaging test may identify pat...ally fatal heart condition. Researchers used Doppl...diagnose hypertrophic cardiomyopathy earlier in a ...CM) causes thickening of the left ventricle of the...
Other Medicine News:
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
Medicine Products: